Phase 3 N=4 Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)
Anaemia
Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 2; 2; 1; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=212 A Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)
Hemophilia B · Hemophilia A
Primary: Annualized Bleeding Rate (ABR) for Treated Bleeds and All Bleeds During Prospective Data Collection Period in Hemophilia B Participants: Efficacy Analysis Set — 3.61…
Phase 3 N=450 Imipenem/Cilastatin-XNW4107 Versus Imipenem/Cilastatin/Relebactam for Treatment of Participants With Bacterial Pneumonia (XNW4107-302, REITAB-2)
Hospital Acquired Bacterial Pneumonia or Ventilator-Associated Bacterial Pneumonia
Primary: Day 14 All-cause Mortality Rate — 3.0; 2.7 percentage of participants
Phase 3 N=513 A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
Depressive Disorder, Major · Anhedonia
Primary: Change From Baseline to Day 43 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -11.4; -12.3 Units on a scale — p==0.467
Phase 3 N=2,757 Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda
Malaria
Primary: Risk of Having a Composite Adverse Birth Outcome — 222; 261; 255 Participants
Phase 3 N=19,474 The ARCT-154 Self-Amplifying RNA Vaccine Efficacy Study (ARCT-154-01)
COVID-19 Vaccines
Primary: Number of Participants Reporting Solicited Local Adverse Reactions (ARs) — 4060; 909; 467; 416 Participants
Phase 3 N=209 Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa
Hidradenitis Suppurativa
Primary: Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 8 — -21.5; -41.9; -39.3; -25.8 Percentage change — p=0.697
Phase 3 N=620 Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)
Schizophrenia
Primary: Change From Baseline in Overall Composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery…
Phase 3 N=73 MIS-C Comparative Effectiveness Study
Multisystem Inflammatory Syndrome-Children
Primary: Number of Participants Needing Additional Anti-inflammatory Therapy Within the First Week of First Randomization — 10; 10; 14 Participants
Phase 3 N=809 An Open-label Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
Major Depressive Disorder
Primary: The Number and Percentage of Patients Reporting Treatment Emergent Adverse Events — 548 Participants
Phase 3 N=554 Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression
Bipolar Depression
Primary: Change From Baseline to Day 43 in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score — -18.9; -20.7; -19.7 score on a scale — p=0.514
Phase 3 N=166 Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C (HbA1C) at Week 24 (Combined Ertugliflozin Versus Placebo) — -0.55; 0.12 A1C Percentage
Phase 3 N=20 Prevent Postpartum Hemorrhage in Women With Von Willebrand Disease: The VWD-WOMAN Trial
Von Willebrand Diseases · Postpartum Hemorrhage
Primary: Volume of Quantitative Blood Loss at Delivery — 727.0; 539.7 mL
Phase 3 N=236 New Treatment for Alcohol and Nicotine Dependence
Alcohol Dependence · Nicotine Dependence
Primary: Continuous Smoking Abstinence in the Last 4 Weeks of Treatment Continuous Smoking Abstinence in the Last 4 Weeks of Treatment — 2; 5; 6 participants
Phase 3 N=24 A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)
Cold Agglutinin Disease
Primary: Number of Patients Achieving a Response (R) at Week 24 — 8; 2 Participants